Previous 10 | Next 10 |
NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its third qua...
NEW HAVEN, Conn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will host a Commercial Day...
When fear rules the markets, investors usually have a hard time seeing the long-term benefits of stock investing. Even share prices of companies with potentially solid long-term prospects remain depressed. In such an environment it does become difficult to identify the real winners. The...
NEW HAVEN, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder ...
Summary BioXcel Q2 Earnings: Igalmi's 120mcg & 180mcg dosage forms are available for order through wholesalers starting from early July. SERENITY III pivotal trial studying the at-home usage of BXCL501 in agitation associated with schizophrenia and bipolar disorder is expected...
BioXcel Therapeutics ( NASDAQ: BTAI ) stock fell ~9% on Aug. 9 after Q2 net loss widened year over year. Q2 net loss widened to -$37.67M, compared to -$27.62M in Q2 2021. "We are focused on the commercial launch for our recently FDA approved drug IGALMI whi...
BioXcel Therapeutics, Inc. (BTAI) Q2 2022 Earnings Conference Call August 9, 2022 08:30 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Richard Steinhart - Senior Vice President and Chief Financial Officer Matt Wiley - Chief Commerc...
BioXcel Therapeutics press release ( NASDAQ: BTAI ): Q2 GAAP EPS of -$1.35 misses by $0.12 . As of June 30, 2022, cash and cash equivalents totaled approximately $233.5 million. This excludes $30 million of contributions from the $260 million strategic financing announ...
Commercially launched IGALMI™ (dexmedetomidine) sublingual film for the acute treatment of agitation in bipolar I or II disorder and schizophrenia in adult patients SERENITY III pivotal trial evaluating at-home use of BXCL501 for the acute treatment of agitation in bipolar ...
BioXcel Therapeutics ( NASDAQ: BTAI ) is scheduled to announce Q2 earnings results on Monday, August 9th, before market close. The consensus EPS Estimate is -$1.18 (-6.3% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 ...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...